675 THE RELATIONSHIP OF SERUM IP-10 LEVELS TO HISTOLOGICAL ACTIVITY, SERUM ALT, HCVRNA TITERS AND HCV GENOTYPE IN CHRONIC HCV INFECTION

Hepatitis C virus (HCV) infection results in not only chronic hepatitis and subsequent complications as liver cirrhosis and hepatocellular carcinoma, but also in a significant number of other diseases, the so-called extrahepatic manifestations of chronic HCV infection. In addition to lymphoproliferative and autoimmune disorders discussed in Part 1 of this review, many other diseases turned to be associated with chronic HCV infection. Part 2 of this review is dedicated to the analysis of the relationship of chronic HCV-infection to the development of some endocrine diseases, such as thyroiditis and diabetes mellitus, and cardiovascular disorders. It also provides the characteristics of the currently available antiviral agents and considers whether they may be used in patents with extrahepatic manifestations of chronic HCV infection.

Download Full-text

The relationship of histology to genotype in chronic HCV infection

Liver International ◽

10.1111/j.1600-0676.1997.tb00797.x ◽

2008 ◽

Vol 17 (3) ◽

pp. 144-151 ◽

Cited By ~ 16

Author(s):

Jonathan C. L. Booth ◽

Graham R. Foster ◽

Tanya Levine ◽

Howard C. Thomas ◽

Robert D. Goldin

Keyword(s):

Hcv Infection ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

Relationship Of ◽

The Relationship

Download Full-text

Hepatic resection for two giant hepatocellular carcinoma after oral direct-acting antiviral therapy: Is there a relationship?

Journal of Solid Tumors ◽

10.5430/jst.v8n2p32 ◽

2018 ◽

Vol 8 (2) ◽

pp. 32 ◽

Cited By ~ 1

Author(s):

Mohamed Abdel Wahab ◽

Ahmed Shehta ◽

Mahmoud Ali

Keyword(s):

Hepatocellular Carcinoma ◽

Antiviral Drugs ◽

Hcv Infection ◽

Dramatic Improvement ◽

Direct Acting Antiviral ◽

Increased Risk ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

Direct Acting ◽

The Relationship

Introduction: Direct-acting antiviral drugs have been recently introduced for management of chronic hepatitis C virus (HCV) patients. Those medications have achieved a dramatic improvement of sustained virologic response (SVR) reaching almost 90%. However, reports regarding the increased risk of occurrence or recurrence of hepatocellular carcinoma (HCC) in chronic HCV patients who achieved SVR after direct-acting antiviral drugs are controversial.Methods: We report two cases of giant HCCs complicating chronic HCV infection after direct-acting antiviral drugs-based therapies and were managed by major hepatic resection.Results: Two male patients with chronic HCV infection received several regimens oral direct acting antiviral drugs with a SVR for 3 and 6 months, respectively. They complained of progressive right hypochondrial pain and abdominal enlargement. Two large HCCs were diagnosed (16.2 cm * 17.6 cm * 16.9 cm, and 18 cm * 13 cm * 16.5 cm in dimensions) with markedly elevated serum alpha feto-protein (36,000 and 7,000 ng/ml, respectively). Due to the presence of adequate residual liver volume, the decision was to proceed for surgical resection. Central hepatectomy and extended right hemi-hepatectomy were performed, respectively. Patients had smooth postoperative course and were discharged after 10 and 9 days, respectively.Conclusion: The relationship between direct-acting antiviral drugs and HCC is controversial. Those cases add support to the accumulating literature suggesting the relationship of HCC development in chronic HCV patients receiving direct-acting antiviral drugs. Further prospective studies with adequate long term follow up are needed to prove or disprove this relationship.

Download Full-text

Relationship of chronic HCV infection, intravenous drug use, and psychiatric history to depression and anxiety

The American Journal of Gastroenterology ◽

10.1016/s0002-9270(01)03122-7 ◽

2001 ◽

Vol 96 (9) ◽

pp. S122

Author(s):

R HILSABECK

Keyword(s):

Drug Use ◽

Hcv Infection ◽

Intravenous Drug ◽

Psychiatric History ◽

Intravenous Drug Use ◽

Depression And Anxiety ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

Relationship Of

Download Full-text

Extrahepatic Manifestations and Autoantibodies in Patients with Hepatitis C Virus Infection

Clinical and Developmental Immunology ◽

10.1155/2012/871401 ◽

2012 ◽

Vol 2012 ◽

pp. 1-11 ◽

Cited By ~ 41

Author(s):

Takashi Himoto ◽

Tsutomu Masaki

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Hcv Infection ◽

Hepatitis C Virus Infection ◽

Extrahepatic Manifestations ◽

Autoimmune Thyroid ◽

Organ Specific ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

The Relationship

Patients with chronic hepatitis C virus (HCV) infection frequently have many extrahepatic manifestations, as persistent HCV infection often triggers lymphoproliferative disorders and metabolic abnormalities. These manifestations primarily include autoimmune disorders such as cryoglobulinemia, Sjögren’s syndrome, and autoimmune thyroid disorders. It has been well established that chronic HCV infection plays important roles in the production of non-organ-specific autoantibodies, including antinuclear antibodies and smooth muscle antibodies, and organ-specific autoantibodies such as thyroid autoantibodies. However, the clinical significance of autoantibodies associated with the extrahepatic manifestations caused by HCV infection has not been fully recognized. In this paper, we mainly focus on the relationship between extrahepatic manifestations and the emergence of autoantibodies in patients with HCV infection and discuss the clinical relevance of the autoantibodies in the extrahepatic disorders.

Download Full-text

HCV genotype 2 as a risk factor for reactivation of chronic HCV infection

Gut ◽

10.1136/gut.2005.070649 ◽

2005 ◽

Vol 54 (8) ◽

pp. 1207-1207 ◽

Cited By ~ 16

Author(s):

N Coppola

Keyword(s):

Risk Factor ◽

Hcv Infection ◽

Hcv Genotype ◽

Genotype 2 ◽

Chronic Hcv Infection ◽

Hcv Genotype 2 ◽

Chronic Hcv

Download Full-text

Mitochondrial Antiviral Signaling Protein Variations in Chronic HCV Infection: Correlation with HCV Genotype and Disease Severity

The American Journal of Gastroenterology ◽

10.14309/00000434-201010001-00292 ◽

2010 ◽

Vol 105 ◽

pp. S108-S109

Author(s):

Premashis Kar ◽

Subhash Medhi ◽

Shyam Swargiary

Keyword(s):

Disease Severity ◽

Hcv Infection ◽

Antiviral Signaling ◽

Hcv Genotype ◽

Signaling Protein ◽

Chronic Hcv Infection ◽

Mitochondrial Antiviral Signaling ◽

Chronic Hcv ◽

Mitochondrial Antiviral Signaling Protein

Download Full-text

Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin

The Journal of Infection in Developing Countries ◽

10.3855/jidc.2937 ◽

2013 ◽

Vol 7 (11) ◽

pp. 859-867 ◽

Cited By ~ 2

Author(s):

Refaat Sadeq ◽

Heba Mohtady ◽

Nissreen Al Badawy ◽

Salwa Ibrahim ◽

Abdul Rahman Omar ◽

...

Keyword(s):

Combination Therapy ◽

Liver Enzyme ◽

Wide Spectrum ◽

Hcv Infection ◽

Blood Monocytes ◽

Genotype 4 ◽

Hcv Genotype ◽

Immunological Mechanisms ◽

Chronic Hcv Infection ◽

Chronic Hcv

Introduction: Hepatitis C virus (HCV) infections remain an increasingly prevalent and emergent health problem worldwide, causing a wide spectrum of liver diseases. Combination therapy with pegylated interferon (PEG-IFN) of peginterferon alfa-2a and oral ribavirinis currently recognized as the standard treatment of chronic HCV infection. Several complex immunological mechanisms are involved during the course of HCV treatment using interferons. The role of endogenous interferon gamma (IFNγ) in Egyptian patients infected with chronic HCV and treated with PEG-IFN/ribavirin is uncertain. The goal of this study was to evaluate the association of IFNγ and chronic HCV infection among patients treated with combination therapy of PEG-IFN/ribavirin. Methodology: Samples from 20 patients infected with HCV genotype-4 (HCV-4) and 20 non-infected individuals as healthy controls were used in this retrospective study. IFNγ levels in peripheral blood monocytes were analyzed, along with liver enzyme alanine aminotransferase (ALT) levels, and single nucleotide polymorphism (SNP) of the myxovirus resistance-A (MxA) gene. Results: The results showed that an increase of IFNγ and a decrease of ALT levels in chronic HCV-infected patients after 12 weeks of treatment with combination therapy. Conclusion: Enhanced IFNγ secretion and decreased liver enzyme ALT production are indicative of HCV clearance and improvement of liver function. In addition, the SNP of the MxA gene is an important host genetic factor that independently influenced the response to IFNα in patients with chronic HCV infection, especially in those with a low viral load.

Download Full-text

Effectiveness of directly acting oral antivirals in treatment of chronic HCV infection in children - experience from a tertiary care institute in southern India

International Journal of Advances in Medicine ◽

10.18203/2349-3933.ijam20210262 ◽

2021 ◽

Vol 8 (2) ◽

pp. 191

Author(s):

Senthil Kumar Ramalingam ◽

Winston Thomas ◽

Nirmala Dheivamani ◽

Sathish Kumar Elumalai

Keyword(s):

Treatment Options ◽

Tertiary Care ◽

Hcv Infection ◽

Hcv Rna ◽

Genotype 1 ◽

Genotype 3 ◽

Hcv Genotype ◽

Chronic Hcv Infection ◽

Hcv Genotype 1 ◽

Chronic Hcv

Background: Worldwide, an estimated 71 million people are chronically infected with HCV, of which an estimated 2.1- 5.0 million are children aged ≤15 years. Children with chronic HCV infection have fewer treatment options than adults. Very few reports are available on HCV infection, treatment strategies and its outcome particularly in pediatric population. In this background, we evaluated the effectiveness and safety of Sofosbuvir/Ledipasvir in treating HCV infection in children.Methods: In this retrospective study, a total of 33 children with HCV positive status, 12 cases (children above 12 years of age) were selected for treatment. HCV-RNA quantitative assay, genotyping was carried out. Children above 12 years with HCV genotype 1 were treated with tablet ledipasvir-sofosbuvir (90/400 mg) orally once a day as morning dose for 12 weeks. Children with genotype 3 were treated with sofosbuvir 400 mg and weight based ribavirin for 24 weeks. Viral load was repeated after 12 weeks of completion of treatment with antivirals for sustained virological response (SVR 12).Results: Out of the 12 patients 11 patients had genotype 1 (5/11 had subtype-1a and 6/11 had subtype-1b) infection and only 1 patient has genotype 3 (subtype-3a). All of them attained SVR at the end of 12 weeks. The regimen was well tolerated and there were no side effects noted by the children and their caretakers. Drug compliance and the palatability of the drugs were good.Conclusions: Ledipasvir-sofosbuvir combination was highly effective at treating children with chronic HCV genotype 1 infection. The availability of an all oral, direct-acting antiviral regimen for paediatric population with chronic HCV would improve care for patients who currently have limited treatment options.

Download Full-text